Multisystem Inflammatory Syndrome in Children Related to COVID-19: a Systematic Review
Overview
Affiliations
An association between a novel pediatric hyperinflammatory condition and SARS-CoV-2 was recently published and termed pediatric inflammatory multisystem syndrome, temporally associated with SARS-CoV-2 (PIMS-TS) or multisystem inflammatory syndrome (in children) (MIS(-C)). We performed a systematic review and describe the epidemiological, clinical, and prognostic characteristics of 953 PIMS-TS/MIS(-C) cases in 68 records. Additionally, we studied the sensitivity of different case definitions that are currently applied. PIMS-TS/MIS(-C) presents at a median age of 8 years. Epidemiological enrichment for males (58.9%) and ethnic minorities (37.0% Black) is present. Apart from obesity (25.3%), comorbidities are rare. PIMS-TS/MIS(-C) is characterized by fever (99.4%), gastrointestinal (85.6%) and cardiocirculatory manifestations (79.3%), and increased inflammatory biomarkers. Nevertheless, 50.3% present respiratory symptoms as well. Over half of patients (56.3%) present with shock. The majority of the patients (73.3%) need intensive care treatment, including extracorporal membrane oxygenation (ECMO) in 3.8%. Despite severe disease, mortality is rather low (1.9%). Of the currently used case definitions, the WHO definition is preferred, as it is more precise, while encompassing most cases.Conclusion: PIMS-TS/MIS(-C) is a severe, heterogeneous disease with epidemiological enrichment for males, adolescents, and racial and ethnic minorities. However, mortality rate is low and short-term outcome favorable. Long-term follow-up of chronic complications and additional clinical research to elucidate the underlying pathogenesis is crucial. What is Known: • A novel pediatric inflammatory syndrome with multisystem involvement has been described in association with SARS-CoV-2. • To date, the scattered reporting of cases and use of different case definitions provides insufficient insight in the full clinical spectrum, epidemiological and immunological features, and prognosis. What is New: • This systematic review illustrates the heterogeneous spectrum of PIMS-TS/MIS(-C) and its epidemiological enrichment for males, adolescents, and racial and ethnic minorities. • Despite its severe presentation, overall short-term outcome is good. • The WHO MIS definition is preferred, as it is more precise, while encompassing most cases.
Progress on diagnosis and treatment of multisystem inflammatory syndrome in children.
Peng Z, Zhou G Front Immunol. 2025; 16:1551122.
PMID: 40046058 PMC: 11879827. DOI: 10.3389/fimmu.2025.1551122.
Depciuch J, Sieminska I, Jakubczyk P, Klebowski B, Ptak K, Szymonska I Sci Rep. 2025; 15(1):4669.
PMID: 39920293 PMC: 11805954. DOI: 10.1038/s41598-025-88976-4.
Li R, Chen P, Li H, Ren L, Cheng Y, Liu L Gastroenterol Res Pract. 2025; 2025:1868214.
PMID: 39850808 PMC: 11756934. DOI: 10.1155/grp/1868214.
Takane-Cabrera I, Ortega-Vargas F, Diaz-Torres I, Herrera-Gonzalez A, Villa A, Garcia-Leon M Front Pediatr. 2025; 12():1440107.
PMID: 39840319 PMC: 11745888. DOI: 10.3389/fped.2024.1440107.
Inflammatory Heart Disease in Multisystem Inflammatory Syndrome.
La Vecchia G, Del Buono M, Bonaventura A, Vecchie A, Moroni F, Sanna T Curr Cardiol Rep. 2025; 27(1):10.
PMID: 39775145 PMC: 11711706. DOI: 10.1007/s11886-024-02173-9.